Healthcare / BiotechnologyToronto
$0.15
+0.02 (+10.71%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-18.9M · quality 67.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$54M
P/E
N/A
•EV/EBITDA
N/A
•ROE
62.8%
↑Gross Margin
N/A
•Debt/Equity
-0.19
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.69x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-15.7M · FCF $-10.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Net Income | $-15.7M | $-15.7M | $-32.2M | $-39.0M | $-24.4M |
| EBITDA | $-14.6M | $-14.6M | $-31.1M | $-38.5M | $-23.9M |
| EPS | -0.05 | -0.05 | -0.10 | -0.13 | -0.09 |
| Balance Sheet | |||||
| Debt/Equity | -0.19 | -0.19 | -0.04 | 0.01 | 0.01 |
| Current Ratio | 0.03 | 0.03 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-10.9M | $-10.9M | $-18.9M | $-30.4M | $-14.8M |
| Returns | |||||
| ROE | 62.8% | 62.8% | 248.5% | -311.6% | -51.3% |
| Valuation | |||||
| P/B | — | — | — | 19.39 | 5.40 |
| Growth & Yield | |||||
| EPS Growth | 50.0% | 50.0% | 23.1% | -44.4% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-13.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.10 → -0.05
Residual
-13.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.